Conditions:  Hereditary Pancreatic Carcinoma;  Pancreatic Adenocarcinoma;  Pancreatic Intraductal Papillary-Mucinous Neoplasm
Interventions: Â Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Â Drug:Â Ferumoxytol
Sponsors:  OHSU Knight Cancer Institute;  National Institute for Biomedical Imaging and Bioengineering (NIBIB);  Oregon Health and Science University
**RECRUITING NOW**
Interventions: Â Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Â Drug:Â Ferumoxytol
Sponsors:  OHSU Knight Cancer Institute;  National Institute for Biomedical Imaging and Bioengineering (NIBIB);  Oregon Health and Science University
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
